2025-524814-27-00
Recruiting
Phase 1
Phase I, first-in-human clinical trial to evaluate safety of infusion of STAb-T19 cells: genetically modified T lymphocytes secreting αCD19xαCD3 bispecific antibodies for malignant B-cell neoplasms
Fundacion Para La Investigacion Biomédica Del Hospital Universitario 12 De Octubre4 sites in 1 country24 target enrollmentStarted: June 1, 2026Last updated:
ConditionsMalignant B-cell neoplasms
Overview
- Phase
- Phase 1
- Status
- Recruiting
- Sponsor
- Fundacion Para La Investigacion Biomédica Del Hospital Universitario 12 De Octubre
- Enrollment
- 24
- Locations
- 4
Overview
Brief Summary
No summary available.
Eligibility Criteria
- Ages
- 18 years to 65+ years (18-64 Years, 65+ Years)
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Investigators
Dra. María Liz Paciello Coronel
Scientific
Fundacion Para La Investigacion Biomédica Del Hospital Universitario 12 De Octubre
Study Sites (4)
Loading locations...
Similar Trials
Recruiting
Phase 1
First in human clinical trial to evaluate the safety, tolerability and preliminary efficacy of the bispecific CD276xCD3 antibody CC-3 in patients with colorectal cancer2022-503084-15-00Deutsches Krebsforschungszentrum (DKFZ)77
Recruiting
Phase 1
A Phase 1 Prospective, Open-label, First-in-human Study to Evaluate the Safety, Tolerability and Biodistribution of [177Lu]Lu-AKIR001 and its Anti-tumour Effect in Adult Patients with CD44v6 Expressing Solid Tumours2023-508126-95-00Karolinska University Hospital30
Recruiting
Phase 1
A first-in-human, phase I, single-center, open-label, dose-escalation trial in healthy volunteers to assess safety, tolerability, and immunogenicity of PANHPVAX, a vaccine targeting human papilloma L2 antigen formulated with cyclic di-AMP2024-511493-67-00Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts45
Completed
Phase 1
A Phase 1 Multicenter, Open Label, First-in-Human Dose Escalation Study of AFM28, a Bispecific ICE® that Targets CD123 and CD16A, in patients with CD123-Positive Relapsed/Refractory Acute Myeloid Leukemia2023-510021-16-00Affimed GmbH60
Recruiting
Not Applicable
A Phase 1/2 Study of KK2430 in Participants with with Hematologic NeoplasmsHematologic NeoplasmsjRCT203126006420